[±Û·Î¹úÁ¦¾à] oncology msl (medical science liasion) ä¿ë°ø°í |
![]() ![]() ![]() ![]() |
¿±â |
ȸ»ç¸í | (ÁÖ)½áÄ¡Æ÷¸®´õ½º |
¸ðÁýºÐ¾ß | ÀϹݰú |
¸ðÁýºÎ¹® | [±Û·Î¹úÁ¦¾à] oncology msl (medical science liasion) ä¿ë°ø°í |
°í¿ëÇüÅ | Á¤±ÔÁ÷ |
¸ðÁýÀοø | 0¸í |
±Þ¿©Á¶°Ç | ¸éÁ¢½Ã ÇùÀÇ |
±Ù¹«Áö¿ª | ¼¿ï |
°æ·Â | °æ·Â 2³âÀÌ»ó |
Çз | °íµîÇб³ Á¹¾÷ |
¸¶°¨ÀÏ | ¸¶°¨¿Ï·á |
Áö¿ø¹æ¹ý | ȨÆäÀÌÁö |
»ó¼¼³»¿ë
|
||||||
Á¤±ÔÁ÷ ´ëÁ¹ÀÌ»ó °æ·Â2³âÀÌ»ó ÀÚ¿¬°úÇаè¿
ÀÇ/¾àÇÐ°è¿ ¿µ¾î ¹«°ü ¾à¹«¡¤Á¦¾à > ¾à»ç, Á¦¾à¿¬±¸°³¹ß, cra °£È£¡¤°£º´ > ¿¬±¸°£È£»ç(crc) Àǻ硤¼öÀÇ»ç > ÀϹÝÀÇ»ç 0¸í ÇùÀÇ ÈÄ °áÁ¤ [±Û·Î¹úÁ¦¾à] oncology msl (medical science liasion) ä¿ë°ø°í ¸ðÁýºÎ¹® ¹× ÀÚ°Ý¿ä°Ç
±Ù¹«Á¶°Ç
ÀüÇü´Ü°è ¹× Á¦Ãâ¼·ù
Á¢¼ö¹æ¹ý 2022-06-19 (ÀÏ) 23½Ã59ºÐ±îÁö
±âŸ À¯ÀÇ»çÇ×
• responsible for daiichi-sankyo oncology pipelines and products • attending external national and international scientific meetings • supporting regulatory affairs and pricing & reimbursement • preparing and conducting advisory board meeting or consulting meeting • recommending local kols for global or regional abms and supporting the events • conducting drug access program such as compassionate use program or expanded access program • supporting commercial drug access program such as patient access program in collaboration with marketing • supporting rmp in collaboration with pv and ra • providing scientific training for sales, marketing, or other internal stakeholders • conducting training or small group seminar, symposium on scientific/medical information to external stakeholder • preparing and conducting medical exhibition booth at medical conference • visiting kols regularly • creating and updating kols list and key society events < scientific research> • providing recommendations for investigators based on the researcher¡¯s interests and qualifications • identifying opportunities for potential external research collaborations • participating ds-sponsored feasibility process and site initiation visit. • engaging medical query during ds-sponsored trials • conducting and liaison for the clinical investigator-initiated study (iis) and pre-clinical investigator-initiated study (material transfer management) < scientific communication> • providing oncology medical information with regard to approved products to internal/external stakeholders • responding to unsolicited questions from external stakeholders with regard to pipeline portfolio • meeting with peer group regularly for formal shared learning and • share learning from publications, external medical conferences and other appropriate internal channels • sharing feedback from external experts including their perspectives on data and medical/scientific needs, views of the general therapeutic area landscape, and clinical experiences • providing recommendations to internal stakeholders for kols and other external parties to serve as consultants or speaker < general affairs> • preparing and maintaining msl log or regular internal reporting process • ensuring budget expense and forecasting À̷¼, °æ·Â¼Ò°³¼ (¿µ¹®, ±¹¹®) ¼¿ïƯº°½Ã > Áß±¸ ÈÞ¹«ÇüÅÂ:ÁÖ5Àϱٹ« ÈÞ°¡:³âÂ÷ 4´ëº¸Çè:±¹¹Î¿¬±Ý,ÀǷẸÇè,»êÀ纸Çè,°í¿ëº¸Çè ~ 2022³â 6¿ù 23ÀÏ ¸ñ¿äÀÏ  (¡æ¸¶°¨±îÁö 29ÀÏ ³²¾Ò½À´Ï´Ù.) ÀÎÅ©·çÆ® ä¿ë½Ã½ºÅÛÀ¸·Î ÀÔ»çÁö¿ø, À̸ÞÀÏ ÀÔ»çÁö¿ø 60 ¼¿ïƯº°½Ã Áß±¸ ¼¿ï °æ·Â2³âÀÌ»ó 2022-06-23 02 y |
||||||
º¹¸®ÈÄ»ý
|
||||||
ÈÞ¹«ÇüÅÂ:ÁÖ5Àϱٹ«
ÈÞ°¡:³âÂ÷ 4´ëº¸Çè:±¹¹Î¿¬±Ý,ÀǷẸÇè,»êÀ纸Çè,°í¿ëº¸Çè |
||||||
Á¦Ãâ¼·ù
|
||||||
À̷¼, °æ·Â¼Ò°³¼ (¿µ¹®, ±¹¹®)
|
¸¶°¨ÀÏ :
2022³â 06¿ù 23ÀÏ (¸¶°¨¿Ï·á)
|
ȨÆäÀÌÁö |
![]() |
![]() |